
GITNUXSOFTWARE REVIEW
International MarketsTop 10 Best Market Access Consulting Services of 2026
Compare market access consulting services and fit for decision makers, with editorial notes on providers like Charles River Associates.
How we ranked these tools
Vendors set the topic, but our editors set the inclusion criteria and the evaluation framework before research starts.
AI search agents find sources, extract figures with provenance, and aggregate written reviews. They also transcribe video reviews and podcasts.
Framework: Features 40% · Ease 30% · Value 30%
Gitnux may earn a commission through links on this page. This does not influence our reviews. Editorial policy
RTI Health Solutions is the best overall pick for payer pathway risk and evidence planning that needs an outside, evidence-first team because it builds study concepts and plans by tying payer reimbursement requirements directly to draft dossier content, while Charles River Associates is the stronger choice for multi-payer teams that need economics-led, decision-grade reimbursement and evidence outputs.
Editor’s top 3 picks
Three quick recommendations before you dive into the full comparison below — each one leads on a different dimension.
RTI Health Solutions
Evidence generation plan development that ties payer evidence requirements to draft dossier content and study concepts.
Best for: Fits when payer pathway risk and evidence planning must be handled by external experts.
Putnam Associates
Editor pickPayer evidence requirements mapping that traces each payer expectation to specific evidence gaps and dossier implications.
Best for: Fits when pharma teams need reimbursement pathway decisions translated into payer-ready evidence plans.
Charles River Associates
Editor pickEconomics-first reimbursement and pricing strategy work that ties payer evidence needs to concrete dossier and submission decisions.
Best for: Fits when pharma teams need analytically rigorous reimbursement strategy and evidence planning across multiple payers.
Comparison Table
RTI Health Solutions
specialistHealth economics and outcomes research organization providing market access evidence generation and consulting.
Evidence generation plan development that ties payer evidence requirements to draft dossier content and study concepts.
RTI Health Solutions is most effective for teams that need structured market access strategy backed by reimbursement feasibility logic and evidence planning. Payer landscape assessment and reimbursement pathway analysis map payer decision points to the proof requirements that later feed value dossier drafting and HTA submission packages. The firm’s work style is geared toward stakeholder mapping and payer engagement inputs that can be converted into an actionable launch plan and submission narrative.
A tradeoff appears when internal teams expect automation-first workflows or self-serve configuration, because RTI Health Solutions is consultative and deliverable-led rather than tool-led. RTI Health Solutions fits usage situations where a payer-driven question needs expert interpretation and synthesis, such as correcting pathway assumptions before primary research begins or tightening the evidence package before submission development.
- +Clear link from reimbursement pathway logic to evidence plan deliverables
- +Strong payer engagement support for stakeholder mapping and interview synthesis
- +Experienced HEOR-to-submission translation for HTA and reimbursement packages
- +Consistent documentation that supports cross-functional review cycles
- –Consulting-led delivery leaves limited automation surface for self-serve teams
- –Requires active sponsor input for scoping payer evidence generation assumptions
- –Best results depend on timely access to internal clinical and commercial data
- –Less suitable for teams seeking an API-first workflow system
Market access strategy teams
Early payer pathway scoping
Fewer pathway assumption changes
HEOR and biostats leads
Evidence plan and endpoints alignment
More focused study execution
Show 2 more scenarios
Pricing and reimbursement teams
Value dossier narrative building
More coherent reimbursement story
Builds a value dossier that matches reimbursement submission logic and payer decision criteria.
Clinical development teams
Comparative evidence gap definition
Clearer evidence generation priorities
Identifies evidence gaps and translates them into study concepts aligned to payer expectations.
Best for: Fits when payer pathway risk and evidence planning must be handled by external experts.
Putnam Associates
specialistLife sciences strategy consulting firm with market access and commercial strategy capabilities.
Payer evidence requirements mapping that traces each payer expectation to specific evidence gaps and dossier implications.
Putnam Associates is a strong fit for teams coordinating payer evidence requirements, payer engagement plans, and reimbursement submission materials across multiple geographies or payer types. The deliverables typically emphasize reimbursement pathway analysis and payer evidence requirements mapping rather than generic competitive benchmarking. Analysts convert payer policy signals into concrete implications for evidence generation plans and value dossier content. This creates usable artifacts for internal governance and external discussions with payers, HTA bodies, and advisory stakeholders.
A key tradeoff is that the work is consulting-led, so it depends on timely access to product data, protocol constraints, and commercial assumptions from the client. The most effective usage situation is early in the launch planning cycle, when pathway constraints and payer expectation gaps can be resolved before study timelines harden. Teams that enter late in the process often find that evidence generation planning and dossier shaping require rapid rework of upstream assumptions.
- +Reimbursement pathway analysis maps payer policy to execution decisions
- +Deliverables connect payer evidence requirements to evidence generation plans
- +Strong coverage policy and formulary positioning support for launch timing
- +Clear stakeholder mapping for payer engagement and negotiation prep
- –Consulting-led delivery requires client-provided data and timely reviews
- –Automation depth is limited compared with software-first market access tooling
- –Late-stage starts can force rework of evidence and dossier assumptions
Market access strategy teams
Build global payer evidence plan
Gaps ranked by payer impact
Medical affairs leaders
Align comparative evidence to dossiers
Study objectives tied to payers
Show 1 more scenario
Commercial and pricing teams
Prepare payer engagement strategy
Negotiation themes with payer logic
Synthesizes coverage policy signals into stakeholder mapping and negotiation preparation materials.
Best for: Fits when pharma teams need reimbursement pathway decisions translated into payer-ready evidence plans.
Charles River Associates
enterprise_vendorConsulting firm offering life sciences advisory including market access, pricing, and health economics.
Economics-first reimbursement and pricing strategy work that ties payer evidence needs to concrete dossier and submission decisions.
Charles River Associates is a fit for teams that need economics modeling rigor and payers- and systems-level reasoning, not just market narrative. Engagements commonly produce clear reimbursement pathway artifacts, payer landscape assessments, and evidence generation plans that link evidence needs to dossier and payer submission activities. Analysts also support formulary positioning choices through coverage policy analysis and scenario framing for launch sequences.
A tradeoff is that CRA delivery style prioritizes analytical depth over rapid turnaround for highly iterative workshops. It performs best when a team can provide access to internal clinical and commercial inputs early and commit to structured stakeholder sessions tied to decision milestones.
- +Economics-driven reasoning that strengthens payer negotiation positions
- +Decision-grade reimbursement pathway outputs for cross-functional alignment
- +Evidence generation roadmaps mapped to payer submission requirements
- +Experienced facilitation for payer engagement strategy planning
- –Not optimized for rapid, highly iterative workshop cycles
- –Stakeholder availability delays can slow evidence-plan finalization
- –Requires strong client inputs to keep analyses decision-relevant
- –Less suited to lightweight desk research without modeling depth
Market access strategy teams
Design payer evidence generation plan
Aligned evidence roadmap
Commercial leadership
Set launch pricing and access approach
Consistent launch positioning
Show 2 more scenarios
Medical affairs
Plan comparative and real-world evidence
Prioritized evidence program
Build evidence generation guidance for payer-facing claims and study design prioritization.
Regulatory and HEOR
Support submission pathway readiness
Submission-ready evidence logic
Map evidence and analytics needs to HTA submission and reimbursement preparation workflows.
Best for: Fits when pharma teams need analytically rigorous reimbursement strategy and evidence planning across multiple payers.
ZS
enterprise_vendorSales, marketing, and strategy consulting firm with a dedicated market access practice for life sciences.
Global value dossier development that aligns payer evidence requirements to dossier content across multiple submission timelines.
ZS provides market access consulting for pharma and life sciences, with a services-heavy delivery model anchored in payer strategy, evidence planning, and reimbursement execution support. The firm routinely maps payer coverage and clinical expectations into structured pathway recommendations that connect dossier content to payer evidence requirements.
- +Structured payer landscape assessments that translate into clear reimbursement pathway actions
- +Evidence generation planning tied to payer evidence requirements for submissions and negotiations
- +Global value dossier support with consistent messaging across multi-country market access workstreams
- +Cross-functional market access launch planning that connects strategy to execution tasks
- –Service-led delivery can reduce self-serve control for teams needing hands-on tooling
- –Automation depth and API surface are not the focus for client integration
- –Governance tooling like RBAC and audit log controls are not central to the offering
- –Effort can concentrate on analyst review, which raises lead-time for iterative stakeholder cycles
Market access research teams
Design payer evidence for coverage decisions
Decision-ready reimbursement findings
Competitive intelligence teams
Create competitor baselines for launches
Launch guidance inputs
Show 2 more scenarios
Commercial strategy teams
Synthesize expert interviews into access strategy
Qualitative decision insights
Plans structured stakeholder and expert interviews and converts findings into strategic implications for market decisions.
Commercial analytics teams
Support pricing and access forecasting
Forecasted decision workflows
Uses analytics, optimization, and forecasting to power operational commercial decisions tied to business priorities.
Best for: Fits when global pharma teams need evidence-led payer strategy delivered through end-to-end market access workstreams.
Deloitte
enterprise_vendorBig Four professional services firm offering life sciences market access and pricing consulting.
Payer and HTA evidence requirements mapping built to translate into a structured evidence generation plan for submissions and payer reviews.
Deloitte is a market access consulting provider built for pharma and life sciences teams that need end-to-end payer strategy and execution support across complex geographies. Its engagements typically cover reimbursement pathway analysis, evidence requirements mapping, and stakeholder and payer engagement planning that aligns with HTA and payer review timelines.
- +Integrated reimbursement pathway analysis with payer and HTA evidence requirement mapping
- +Strong stakeholder mapping and payer engagement planning for structured advocacy
- +Consulting delivery model supports complex global submissions coordination
- +Clear linkage from evidence generation plans to payer evidence needs
- –Less suited for teams needing self-serve automation without consulting work
- –Requires detailed internal input to keep payer assumptions consistent across markets
- –Governance and review cycles can extend timelines for iterative strategy changes
- –Limited fit for narrow, single-asset projects without broader launch context
Deal teams and finance leaders
Build defensible valuation for regulated assets
Review-ready valuation package
Marketing analytics stakeholders
Model channel effects for access planning
Documented modeling insights
Show 2 more scenarios
Enterprise transformation leaders
Redesign operating model for reimbursement execution
Structured execution roadmap
Redesigns value chains and business processes while coordinating workstreams to deliver aligned decisions and measurable outcomes.
Enterprise marketing teams
Transform loyalty rules for managed access
Governed loyalty structure
Designs loyalty operating models, identity approaches, migration steps, and earn and redemption measurement.
Best for: Fits when pharma teams need consulting-led market access strategy and evidence planning across multiple payer environments.
Analysis Group
enterprise_vendorEconomics consulting firm with a health sciences practice providing market access and HEOR support.
Reimbursement pathway analysis that links payer evidence requirements to a sequenced evidence generation plan for submissions.
Analysis Group delivers market access consulting work for pharma and life sciences teams focused on reimbursement and payer decision making. The firm pairs payer landscape assessment with reimbursement pathway analysis and HTA-informed evidence planning across major markets.
- +Evidence planning grounded in payer and HTA evidence requirements
- +Budget impact modeling support tied to reimbursement pathway assumptions
- +Comparative evidence and CER inputs for value dossier narratives
- +Clear stakeholder mapping outputs for payer engagement planning
- –Delivery depends on client-provided data quality and access timelines
- –Automation and API surface is not a native capability for request workflow
- –Governance artifacts like RBAC and audit logs are not a published focus
- –Model iteration cycles require structured change management from teams
Pharma market access teams
Build economic models for payer discussions
Structured dossier-oriented economics
Corporate strategy teams
Connect market evidence to access decisions
Evidence-linked decision output
Show 2 more scenarios
Securities litigators and regulators
Quantify market impact evidence
Evidence-based impact analysis
Applies event studies and econometric methods to evaluate causation and financial loss tied to events.
Trial counsel teams
Prepare research-led payer evidence narratives
Prepared argument strategy
Studies venue and audience attitudes to inform messaging and witness preparation using research-led recommendations.
Best for: Fits when global pharma teams need reimbursement strategy and evidence planning across multiple payer and HTA contexts.
Simon-Kucher & Partners
enterprise_vendorGlobal strategy consulting firm specializing in pricing and market access for pharmaceutical clients.
Evidence generation planning that maps payer evidence requirements directly to dossier structure and submission-ready outputs.
Simon-Kucher & Partners runs market access consulting engagements that translate payer and HTA requirements into a measurable reimbursement path. Teams get payer landscape assessment, evidence generation planning, and value dossier support for both global and country submission workflows.
- +Connects reimbursement submission content to payer evidence requirements and pathway logic
- +Produces structured value dossier materials for global and local payer contexts
- +Builds budget impact model assumptions around access scenarios and launch constraints
- +Supports payer engagement planning with stakeholder mapping and KOL interview inputs
- –Requires tight internal access to clinical and operational inputs for evidence planning
- –Automation and API surfaces are not a native part of the service delivery
- –Governance and review cycles can extend timelines for iterative payer feedback loops
- –Less suited to teams needing tooling for real-time payer intelligence monitoring
Go-to-market launch teams
Align value proposition with reimbursement path
Coordinated launch strategy
Growth marketing leaders
Refine segment positioning for access
Segment-specific recommendations
Show 2 more scenarios
Healthcare commercial teams
Create market-entry choices grounded in value
Value-based entry guidance
Applies pricing and value methods to inform commercialization decisions for healthcare and life sciences products.
Pricing and revenue leaders
Quantify trade-offs for price changes
Quantified pricing direction
Evaluates willingness-to-pay, segment differences, and packaging implications to guide pricing direction and rollout.
Best for: Fits when pharma teams need end-to-end market access strategy artifacts linked to reimbursement pathway execution.
LEK Consulting
enterprise_vendorGlobal strategy consulting firm with a life sciences practice covering market access and commercial strategy.
Payer evidence requirements mapping that ties reimbursement pathway decisions to an actionable evidence generation plan.
LEK Consulting delivers market access consulting grounded in payer landscape assessment and reimbursement pathway analysis for pharma and life sciences teams. Its work emphasizes payer evidence requirements, from pathway design through evidence generation planning and launch readiness.
- +Strong payer landscape assessment outputs aligned to reimbursement pathway steps
- +Evidence generation plan deliverables connect data needs to payer evidence expectations
- +Clear stakeholder mapping artifacts for payer engagement and KOL interview preparation
- +Structured support for HTA submission and reimbursement submission materials
- –Deliverables often require internal teams to implement timelines and data collection
- –Less operational guidance for coding and billing assessments than evidence and pathway work
- –Automation and API surface are not part of the engagement deliverables
Life sciences market access teams
Plan evidence generation for reimbursement
Evidence generation execution plan
Procurement and supply chain leaders
Use market analysis for sourcing decisions
Market-informed supply strategy
Show 2 more scenarios
Corporate strategy and expansion leaders
Plan a new market entry roadmap
Implementation-ready entry roadmap
Assesses country conditions, competitors, and operating choices to produce a market-entry recommendation and roadmap.
Private equity deal teams
Assess acquisition target market fit
Strategic fit assessment
Evaluates market demand, competitive position, and growth assumptions to inform transaction decisions.
Best for: Fits when global and country teams need payer-informed strategy that converts into evidence plans.
Health Advances
specialistHealthcare strategy consulting firm advising on market access, reimbursement, and commercialization.
Dossier-aligned evidence generation planning that converts payer evidence requirements into an actionable submission narrative.
Health Advances delivers market access consulting for pharma and life sciences teams that need payer landscape assessment and reimbursement pathway analysis across specific countries or therapy areas. The work centers on translating payer evidence requirements into a structured evidence generation plan and a payer engagement workflow for internal and external stakeholders.
- +Clear reimbursement pathway mapping tied to concrete stakeholder actions
- +Evidence generation plan outputs align with payer evidence requirements
- +Consistent synthesis of payer landscape assessment into submission-ready narrative logic
- +Direct support for payer engagement planning and KOL or advisory board workflows
- –Depth varies by geography when evidence and payer policy signals are limited
- –Requires strong client inputs on clinical data access and study artifacts
- –Automation and API surfaces are not a stated capability in engagement materials
- –Less suited to purely data-pipeline work without a consulting-led evidence build
Pharma and biotech market access
Write payer-oriented reimbursement evidence narratives
Structured reimbursement materials
Diagnostics and digital health strategy
Assess opportunity using treatment pathway mapping
Prioritized opportunity view
Show 2 more scenarios
Provider and health system executives
Translate clinical operations into access execution
Access and capacity roadmap
Maps clinical workflows and produces governed roadmaps with tracked decisions and baseline measures.
Commercialization leaders
Plan market entry and launch direction
Evidence-informed commercialization path
Builds commercialization paths by integrating market, clinical, and stakeholder evidence for healthcare products and services.
Best for: Fits when medical, HEOR, and market access teams need consulting-led reimbursement strategy execution.
Certara
enterprise_vendorBiosimulation and drug development services company with market access and HEOR consulting.
Traceable evidence generation plan mapping that ties payer evidence requirements to specific study outputs and dossier sections.
Certara is a market access consulting provider that combines payer-focused strategy work with analytic capabilities grounded in pharma drug development methods. The firm supports reimbursement pathway analysis, value dossier preparation, and evidence generation planning using structured stakeholder inputs and study-ready evidence.
- +Evidence planning links payer evidence requirements to dossier inputs
- +Structured payer landscape assessment supports regional reimbursement pathway choices
- +Experience across HTA-style evidence formats strengthens submission readiness
- +Consulting workflow supports cross-functional alignment with clinical teams
- –Engagements require high internal data availability to reach dossier-grade outputs
- –Automation depth depends on client tooling and integration choices
- –Governance artifacts like RBAC and audit log patterns are not packaged as standard software
- –Timelines can stretch when payer assumptions need iterative rework
Discovery scientists
Apply computational screening within programs
Earlier computational assessment
Regulatory writing teams
Convert study evidence into payer-ready narratives
Consistent evidence documents
Show 2 more scenarios
Regulatory submission operations
Coordinate dossier production across regions
Controlled dossier deliverables
Coordinates submission content, dossier production, publishing, correspondence, and responses across regions to keep deliverables traceable.
Clinical operations teams
Connect trial workflows to downstream reporting evidence
Connected trial and reporting workflows
Supports study startup, trial conduct, and data workflows that feed downstream reporting and evidence generation.
Best for: Fits when pharma teams need traceable evidence logic across payer engagement and dossier deliverables.
Conclusion
After evaluating 10 market access consulting, RTI Health Solutions stands out as our overall top pick — it scored highest across our combined criteria of features, ease of use, and value, which is why it sits at #1 in the rankings above.
Use the comparison table and detailed reviews above to validate the fit against your own requirements before committing to a tool.
Frequently Asked Questions About Market Access Consulting
Which provider work products connect payer evidence requirements to dossier sections without gaps?
How does market access consulting typically handle data migration and upstream input quality for payer pathway analysis?
When does payer engagement planning become a deliverable versus a workshop activity, and who operationalizes it best?
What breaks if internal teams expect automation-first, self-serve configuration during reimbursement pathway work?
Where do payer landscape assessment and reimbursement pathway analysis fall short if the evidence generation plan is not sequenced to submissions?
Which provider approach is strongest for global value dossier development across markets with different evidence expectations?
How do providers differ in translating coverage policy signals into formulary and reimbursement decisions?
Which service is best when the core need is reimbursement submission narrative readiness tied to payer review logic?
What tradeoff occurs when strategy-heavy market access consulting must also deliver analytic rigor?
Tools reviewed
Primary sources checked during evaluation.
Referenced in the comparison table and product reviews above.
How to Choose the Right Market Access Consulting
Options differ most in how well they turn market access consulting work into repeatable deliverables and workflows. We focus on integration depth and audit-ready outputs via criterion labels like evidence generation plan and market access launch plan.
Evidence generation plan builder
Why it matters
Evidence generation plan builder support matters because market access consulting often hinges on documenting what proof will be gathered, by whom, and when. Without a concrete plan, teams usually redo work across countries and timelines.
How to check
Ask to see a sample project template where you enter therapeutic area, target market, and evidence gaps, then generate an evidence generation plan with tasks and owners. Check whether it outputs a shareable document format and whether updates preserve prior versions.
Payer requirements traceability
Why it matters
Payer evidence requirements traceability matters because consulting teams must align submitted claims to payer expectations and avoid rework. Good traceability reduces gaps between what the dossier says and what reviewers look for.
How to check
Request a workflow demo where you link evidence items to specific payer evidence requirements for multiple markets. Then click through one requirement to see which evidence artifacts satisfy it and what coverage is missing.
Value dossier production workflow
Why it matters
Value dossier production workflow is a differentiator because consulting deliverables must stay consistent across drafts and reviewers. Where the workflow is thin, teams manually stitch content and introduce inconsistencies.
How to check
Ask for a walkthrough that starts from inputs (endpoints, comparators, assumptions) and outputs a dossier outline plus a review-ready package. Check whether you can configure section content and generate the same structure across countries with minimal edits.
Automation and API for deliverables
Why it matters
Automation and API surface matters for market access consulting because teams reuse the same artifacts across clients and markets. Strong provisioning and API support reduce turnaround time and reduce formatting drift.
How to check
During the demo, ask what can be automated: generating a dossier package, exporting evidence traces, and syncing updates into a downstream system. If available, request an API sandbox and a simple example call that returns a deliverable package.
Managed entry agreement scenario modeling
Why it matters
Managed entry agreement scenario modeling is valuable because consulting often needs to test different commercial and access conditions before recommendations. Without scenario support, teams lose time recalculating assumptions.
How to check
Ask for a demo where you define conditions (entry triggers, follow-up evaluation, outcomes) and generate scenario outputs. Verify whether the tool shows which assumptions drive differences and whether you can compare scenarios side-by-side.
Red flags
- It only offers document templates without execution workflows
- You can’t trace reviewer-facing claims back to evidence items
- Exports can’t be regenerated consistently from the source plan
Fit by situation
- If we need repeatable deliverables across multiple markets, prioritize Value dossier production workflow.
- If we track evidence gaps and assignments, prioritize Evidence generation plan builder.
- If our team must align claims to payer expectations, prioritize Payer requirements traceability.
Funding and competing interests
This study was co-funded by several of the vendors assessed in it. No single vendor funded it. Funders could propose the market studied.
They had no role in selecting vendors, setting or weighting criteria, analysing data or drawing conclusions, and they received the same factual-accuracy check as every other vendor assessed.
Market definition, inclusion rules and criteria weights were fixed by an editor before research began and did not change afterwards. Editorial process →
- Service review · 2026 · International MarketsFinancial Market
- Service review · 2026 · Digital Transformation In IndustryAccess Consulting
- Service review · 2026 · Market ResearchGrowth Strategy Consulting
- Review · 2026 · International MarketsMarket Access Software
- Review · 2026 · Business Process OutsourcingConsulting Services Software
Keep exploring
Comparing two specific tools?
Software Alternatives
See head-to-head software comparisons with feature breakdowns, pricing, and our recommendation for each use case.
Explore software alternatives→In this category
International Markets alternatives
See side-by-side comparisons of international markets tools and pick the right one for your stack.
Compare international markets tools→